Methods for treatment of patients with myelodysplastic syndromes
AssigneeActinium Pharmaceuticals, Inc.
InventorMark Berger
Life of this patent
Estimating the term…
Abstract
Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.
Claims18
A method of treating a hematologic malignancy in a subject comprising administering to the subject an effective amount of an anti-CD33 targeting agent, wherein the subject has a complex karyotype or a p53 mutation,
- wherein the anti-CD33 targeting agent comprises a radiolabel selected from the group consisting of 131I, 125I, 123I, 90Y, 177Lu, 186Re, 188Re, 89Sr, 153Sm, 32p, 225Ac, 213Bi, 213Po, 211At, 212Bi, 213Bi, 223Ra, 227Th, 149Tb, 137Cs, 212Pb, and 103Pd, and
- wherein the hematologic malignancy comprises myelodysplastic syndrome (MDS), multiple myeloma (MM), acute myeloid leukemia (AML), myeloproliferative neoplasm, or a combination thereof, and
- wherein the anti-CD33 targeting agent comprises lintuzumab, gemtuzumab, or vadastuximab;
- and wherein the effective amount of the anti-CD33 targeting agent is an amount sufficient to induce myeloconditioning, or an amount sufficient to induce myeloabation.
A method for treating a subject having a myelodysplastic syndrome, the method comprising:
- determining if the subject has a complex karyotype as indicated by the myelodysplastic syndrome categorized as a poor or very poor cytogenetic prognostic subgroup in the IPSS-R;
- and
- if the subject has the complex karyotype, proceeding with administration of an effective amount of an anti-CD33 targeting agent,
- wherein the anti-CD33 targeting agent is 131I-or 225Ac-labelled and is administered as a single bolus or infusion in a subject specific dose comprising a radiation dose of 0.1 to 10 uCi/kg body weight of the subject, and a total protein dose of less than 16 mg/kg body weight of the subject, and
- wherein the anti-CD33 targeting agent comprises lintuzumab.
A method for treating a subject having a myelodysplastic syndrome, the method comprising:
- determining if the subject has one or both of a mutated p53 gene or a mutant form of p53 protein;
- and
- if the subject has one or both of the mutated p53 gene or the mutant form of the p53 protein, proceeding with administration of an effective amount of an anti-CD33 targeting agent,
- wherein the anti-CD33 targeting agent is 131I-or 225Ac-labelled and is administered as a single bolus or infusion in a subject specific dose comprising a radiation dose of 0.1 to 10 uCi/kg body weight of the subject, and a total protein dose of less than 16 mg/kg body weight of the subject, and
- wherein the anti-CD33 targeting agent comprises lintuzumab.
Dependencies are inferred from the claim text.